SOCS1 and diffuse large B-cell lymphoma: The comparison of four independent DLBCL studies done by Mellert et al. suggests that SOCS1 mutations may be used to forecast an extremely favorable overall survival rate of early-onset DLBCL patients (aged <60 years) [47].